Articles tagged with Drug Targets
University of Cincinnati researchers are studying whether targeting an inflammation pathway can improve patient results for soldiers with burn injuries combined with traumatic brain injuries. The research focuses on a specific protein that causes inflammation, which can lead to complications such as anemia and death.
Researchers have modelled a key mechanism by which DNA replicates, revealing details about how helicases wrangle DNA during replication. The simulations showed each step of translocation can travel more than 12 nucleotides along the backbone, pinpointing interactions involved in long-distance movement.
Higher aldosterone concentrations are associated with lower eGFR, lower potassium levels in blood, and higher potassium and protein concentrations in urine. The risk of CKD worsening was independent of diabetes status. Finerenone may help prevent CKD progression by targeting aldosterone's action.
A new study provides critical insights into the pGC-A membrane receptor, a vital component of cardiovascular regulation. The research offers a clearer understanding of this complex receptor and its signaling mechanisms, paving the way for new anti-hypertensive drugs.
Leukemia cells exploit metabolic pathways to evade programmed cell death, but researchers identified a weak spot in acute lymphoblastic leukemia that can be targeted with experimental drugs. Inhibiting glutathione metabolism induces ferroptosis, leading to the death of malignant lymphocytes.
Researchers at VCU Massey Cancer Center have discovered a new target for treating high-risk neuroblastoma, a deadly pediatric cancer. A novel compound called SHP099 has shown promising results in shrinking tumors and killing cancer cells.
A new advanced MRI technique has enabled clinicians to measure the effectiveness of chemotherapy in patients with stiff heart syndrome, improving their prognosis. By accurately measuring amyloid protein deposits in the heart, doctors can better guide treatment strategies and improve patient outcomes.
Researchers identified CUDC907 as a dual phosphoinositide-3 kinase/histone deacetylase inhibitor that promotes apoptosis in NF2 schwannoma cells. The compound reduced viability and induced cell cycle arrest in human merlin deficient Schwann cell models.
A study published in JAMA found that FDA warning letters resulted in increased product recalls and the removal of prohibited drugs from dietary supplements. The investigation aimed to assess the frequency of recalls and presence of FDA-prohibited substances after issuing warning letters.
Researchers propose a novel paradigm using nanoscale nonlinear fluid dynamics to support recurrent neural networks in neuromorphic computing. The liquid film functions as an optical memory, enabling 'reservoir computing' capable of performing digital and analog tasks.
Researchers developed a mathematical model to predict the efficiency of nanoparticle delivery into cells, particularly in stem cells. They found that nanoparticles become trapped in bubble-like vesicles, preventing them from reaching their targets.
A preclinical study found that antibiotics have sex-specific effects on the gut microbiome of lab rats, resulting in significant changes in diversity. The findings could have implications for using antibiotics to treat or prevent bacterial infections in humans.
Researchers at Johns Hopkins Medicine have probed the atomic structure of proteins, finding that wiggling and movement play a critical role in their ability to function. The study's findings may help scientists design new drugs that can modify or disrupt protein movements to alter their functions.
Researchers have created a new mouse model that mimics brain damage caused by severe RVFV infection, enabling the study of disease mechanisms and high-throughput testing of next-generation drugs. This breakthrough has significant implications for developing therapies and vaccines for this devastating virus.
Researchers found that men who lose their Y chromosome as they age are more likely to experience deadly heart scarring and earlier death. The study suggests an existing drug may help counteract the effects of this loss, potentially leading to longer, healthier lives for affected men.
Researchers at the University of Birmingham developed a new technique using mass spectrometry to analyze drug-protein interactions in real tissue samples. This allows scientists to predict the therapeutic effect of drugs earlier, enabling more effective treatment options.
The Mount Sinai Hospital has been awarded $4.2 million over five years to establish a Proteogenomic Data Analysis Center, which will help identify potential biomarkers and drug targets for cancer and new insights into cancer biology.
The study found an overall response rate of 32% across all patients with EGFR exon 20 mutations, varying depending on the location of the mutation. Near-loop insertions showed a 46% overall response rate, while far-loop insertions had no response rate.
A new study by the University of Pittsburgh found that patients with diabetes on Medicare Advantage plans are more likely to receive preventive treatments, but less likely to receive newer and more expensive medications. This disparity can lead to poorer health outcomes, including higher blood pressure and worse diabetes control.
A preclinical study by Cedars-Sinai Cancer and Johns Hopkins University has discovered a novel three-step treatment that disrupts the pancreatic tumor microenvironment in laboratory mice. The treatment, which combines anti-PD-1 immunotherapy antibody, FAKi, and CXCR4, prevents cancer metastasis and bolsters the immune system.
Indiana University researchers are using a mouse model to study the effects of cannabis use during adolescence, which could impair working memory and increase the risk of psychosis later in life. The $2M NIH grant aims to develop therapies to treat adverse effects.
A pooled data analysis of available research found that ADHD drugs may successfully treat key aspects of Alzheimer's disease. Noradrenergic drugs, which target the neurotransmitter noradrenaline, showed a small but significant positive effect on overall cognition and a large positive effect on apathy in patients with Alzheimer's disease.
A study published by researchers at the University of Colorado Anschutz Medical Campus found that psychiatric drugs imipramine and olanzapine can improve symptoms of Alzheimer's disease, including boosting cognition and reversing clinical diagnoses.
Researchers discovered that blocking certain acetylcholine receptors in the lateral habenula balances reward and aversion, making it harder to resist seeking cocaine. This finding identifies a new role for these receptors as a potential target for treating cocaine use disorder.
Biomarkers have been identified that could be targeted by novel drugs to treat glioblastoma brain tumors, which are highly lethal. The researchers found that temozolomide-resistant glioblastoma relies on a protein called CLK2, and that inhibiting its activity can cause widespread cancer cell death.
Researchers discovered PDE5 inhibitors can reverse chemotherapy resistance by targeting cancer-associated fibroblasts, potentially shrinking oesophageal tumours more than chemotherapy alone. The treatment is already proven to be safe and well-tolerated, with promising results in a phase I/II clinical trial.
Researchers have developed a framework to analyze chromosomal instability in human cancers, characterizing 17 different types of signatures. These signatures can predict how tumors respond to drugs and help identify future drug targets. The discovery aims to improve survival rates for millions of cancer patients worldwide.
Researchers have developed a molecule that uses nanotechnology, chemotherapy and a monoclonal antibody to target glioblastoma multiforme, the most aggressive type of brain cancer. The treatment showed promise in isolated cells and animal models, with significant reductions in tumor volume and no increased toxicity.
A novel study has identified metabolic defects, impaired protein secretion, and altered phosphoproteomic signatures in alcohol-associated cirrhosis and hepatitis. These findings may lead to the development of new diagnostic and therapeutic approaches for a disease with limited treatment options.
Researchers at the University of Cincinnati are studying how lipids help fortify lung cancer cells and if targeting them can lead to better outcomes. The team discovered that lipids play a crucial role in cancer cell growth, membrane fortification, and energy production.
A recent study published in Frontiers in Cardiovascular Medicine found that transcranial direct current stimulation (tDCS) can lower blood pressure in patients with resistant hypertension. After a single session or ten sessions, the treatment reduced peripheral and central blood pressure in some patients by up to 15 mmHg.
A phase 2 trial of the experimental drug adagrasib showed a 42.9% objective response rate and median overall survival of 12.6 months in patients with KRAS-mutated non-small cell lung cancer. The treatment also achieved a 33.3% response rate in patients with stable brain metastases.
Researchers at Karolinska Institutet found a link between genetic variants in diabetes drug targets and lower Alzheimer's disease risk. The study suggests that the target protein, KATP channel, may be a therapeutic target for treating and preventing Alzheimer's disease.
Researchers have identified new biomarkers to detect non-small cell lung cancer in its early stages through a blood test, offering improved survival chances. The approach can also identify potential drug resistance, allowing clinicians to choose alternative treatment options.
A compound called ERX-41 has been shown to kill a range of hard-to-treat cancer types, including breast and ovarian cancers, by targeting a previously unexploited vulnerability. This could lead to new drugs being developed to fight these cancers, which currently have few effective treatments.
A team of MIT researchers has developed drug-carrying nanoparticles that can efficiently penetrate the brain and kill glioblastoma cells. Using a human tissue model, they showed that the particles could get into tumors and deliver chemotherapy drugs, including cisplatin, which effectively killed tumor cells.
Researchers at Georgia State University have been awarded over $6 million to develop antiviral drugs targeting COVID-19 and other viral threats. The funding will support the establishment of a new Midwest Antiviral Drug Discovery Center, which aims to build a pipeline of antiviral drugs.
A new interactive web portal, SpUR, catalogues over 1,000 splicing events found in cancers, highlighting their role in tumor development and progression. The database provides a platform for researchers to study RNA dysregulations in cancer and develop RNA-based anti-cancer drugs.
Researchers have found that mutational signatures, which reflect a collection of mutations across the genome, can accurately predict drug response in cancer cells. The study suggests that these signatures may hold the key to better cancer therapies and could be used to predict treatment response.
A study by Weill Cornell Medicine investigators has revealed the cause and potential precision therapies for a type of aggressive blood cancer called diffuse large B cell lymphoma (DLBCL). The research found that SETD2 gene mutations can lead to an accumulation of DNA damage, causing cancer cells to grow uncontrollably.
A Johns Hopkins Medicine study found that a protein called STING responds to clean-up signals in brain cells damaged by Parkinson’s disease by creating a cycle of inflammation that accelerates the disease’s progression. In mice with deactivated STING proteins, there was less microglial activity and brain cell death.
A study published in Nature Communications sheds light on dopamine transporter (DAT) function, which regulates brain reward centre communication. The researchers discovered DAT depends on potassium, not just sodium, rewriting textbooks on its mechanism.
Researchers found that targeting both tumor and lymph node microenvironments with nanomedicine improves treatment response for metastatic triple negative breast cancer. Long-term tumor remission was achieved in mice models using nanoparticles to deliver immune-modulating drugs.
Researchers have pinpointed a possible new target for treating patients with juvenile myelomonocytic leukemia (JMML), a highly aggressive blood cancer. Treatment using anti-inflammatories showed promise in rescuing JMML-like symptoms in zebrafish, suggesting a potential new approach to combating the disease.
A new study suggests that supplementing a diet with Ascidiacea, also known as sea squirts, reverses some main signs of aging in animal models. The researchers found that plasmalogens, vital to body processes, decrease with age and contribute to neurodegenerative diseases like Alzheimer's and Parkinson's.
Researchers at the University of Missouri are applying AI to analyze protein dynamics, identifying potential target sites for new drug therapies. The approach can simulate protein changes related to conditions like cancer, enhancing the chances of successful therapies.
A study at the University of Helsinki found that a strong saline solution can quadruple morphine concentration in the spinal cord, intensifying pain relief. The glymphatic system enables faster drug delivery when administered with hypertonic solutions.
Researchers from the US and Japan have discovered the mechanism of GTP recognition by a tumor-promoting kinase, leading to the evolution of a GTP sensor kinase. This finding could lead to the development of a new cancer-treating drug that targets PI5P4Kβ using GTP instead of ATP.
Researchers at Cedars-Sinai have developed an AI tool that accurately predicts pancreatic cancer patients based on CT scan images. Lowering blood cholesterol has also been shown to slow the growth of prostate cancer by enhancing immune cell action. Additionally, a new study found that an ultrasound probe plugged into a smartphone can b...
Researchers found that genetic mutations in the MAPK pathway, key to normal cell growth, can also make head and neck cancer vulnerable. Individualized genomic analysis can identify specific mutations and target drugs, offering a promising approach to precision medicine.
The University at Buffalo is developing new treatments for ovarian cancer by targeting the apelin receptor. Ovarian cancer cells rely on lipids for energy and survival, making this a promising therapeutic target.
Researchers have discovered that palmitoylation can occur at the plasma membrane, paving the way for innovative drug discovery strategies. A novel tool, SwissKASH, allows for dynamic observation of this process, enabling precise targeting of oncogenic proteins in cancer therapy.
Researchers from The University of Texas Health Science Center at San Antonio have identified 33 genes associated with Alzheimer's disease, doubling the known list. This discovery adds 42 new genetic variants to the existing gene list, shedding light on emerging pathways of Alzheimer's biology and potential treatment targets.
A phase two randomised placebo controlled trial showed giving patients nintedanib, as well as chemotherapy before surgery or radiotherapy, significantly increased overall survival rates at one, two and five years. Nintedanib blocks different proteins from sending signals to cancer cells to grow, causing the cancer cells to die.
A recent study suggests that many older adults with rheumatoid arthritis are not prescribed disease-modifying medications, despite guidelines calling for early and aggressive treatment. Only 45% of patients over 65 were prescribed these medications, highlighting the need to improve prescribing practices among primary care physicians.
Recent studies published in the Journal of Pharmaceutical Analysis have found applications of nanotechnology in medicine, drug research, and environmental protection. Researchers developed nanodots made of carbon using natural polysaccharides from mushrooms to detect chromium, and created nanozymes that could be used to detect drug con...
A randomized clinical trial found that participants treated at non-stigmatizing 'accessible care' centers were nearly three times more likely to be cured of hepatitis C than those referred out to local clinicians. The study suggests that expanding and supporting accessible care models could help eliminate the disease.
Researchers at CU Cancer Center have developed a lead drug that inhibits the oncogene CHD1L, a chromatin remodeling enzyme that aids tumor progression and metastasis in many cancer types. The drug, called 6.11, has shown promising biological activity against CHD1L.
Researchers have developed a method to chart the first-ever map of allosteric sites in two common human proteins, revealing they are abundant and identifiable. This could lead to safer, smarter, and more effective medicines by targeting these 'secret doors'.
Researchers at the University of Illinois Chicago have identified two distinct subtypes of neutrophils, with one subtype being a drug target for treating inflammatory diseases. The discovery paves the way for more targeted therapies that address chronic inflammation without suppressing anti-infection functions.